West Pharmaceutical Services (WST) 10-K Summary — Year Ended Dec 31, 2023
West Pharmaceutical Services, Inc. filed its annual report for the most recent fiscal year. The filing provides financial metrics and a trend showing revenue growth, but does not include detailed business or risk narratives in the supplied data.
Key takeaway
Year ended Dec 31, 2023 · FY2025 10-K
West Pharmaceutical Services, Inc. filed its annual report for the most recent fiscal year. The filing provides financial metrics and a trend showing revenue growth, but does not include detailed business or risk narratives in the supplied data.
Financial snapshot
Selected annual figures reported with the filing, shown separately from the narrative summary.
Annual revenue
$2.9B
Revenue reported for the fiscal year.
Operating income
$676M
Income from operations reported for the year.
Net income
$593.4M
Net income reported for the year.
Operating cash flow
$776.5M
Cash generated by operating activities.
Annual revenue trend
Reported annual revenue and its change from the preceding fiscal year.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2021 | $2.8B | n/a |
| Dec 31, 2022 | $2.9B | +2.0% |
| Dec 31, 2023 | $2.9B | +2.2% |
Business overview
The filing references Item 1 for business overview but does not contain the full text. Therefore, no detailed business description is available from the supplied information.
Financial performance
Revenue increased from the prior year and remained relatively stable in the most recent period. The company reported positive operating income and net income, with operating cash flow exceeding net income.
Material risks
The filing references Item 1A for risk factors, but no specific risks are detailed in the supplied data. As such, material risks cannot be identified from the provided context.
Liquidity and capital
The filing references a liquidity and capital resources section, but no specific allocation themes or liquidity details are provided in the supplied data.
What to watch
Monitor the next filing for the inclusion of business and risk factor details to better understand the company's operations and uncertainties.